Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01771666 · ClinicalTrials.gov registry record · Phase 2
Pilot Indocyanine Green Imaging for Mapping of Arm Draining Lymphatics & Nodes in Breast Cancer
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT01771666: Completed Phase 2 study, sponsored by Stanford University.
NCT01771666 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01771666, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if Indocyanine Green (IC-GREEN) is comparable to isosulfan blue (IS-BLUE) in the identification of arm lymphatics and arm-draining nodes during nodal staging procedures in breast cancer.
Interventions
- DRUG Indocyanine Green
- DRUG Isosulfan blue
- DEVICE SPY Elite Imaging
- DRUG 99technetium-sulfur colloid radiolabel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2012-07 |
| Est. Completion | 2015-03-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01771666
The ClinicalTrials.gov registry entry for NCT01771666 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Indocyanine Green is the first listed.
NCT01771666 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01771666 about?
NCT01771666 is a clinical study titled "Pilot Indocyanine Green Imaging for Mapping of Arm Draining Lymphatics & Nodes in Breast Cancer". The purpose of this study is to determine if Indocyanine Green (IC-GREEN) is comparable to isosulfan blue (IS-BLUE) in the identification of arm lymphatics and arm-draining nodes during nodal staging procedures in breast cancer.
What is the current status of trial NCT01771666?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2012-07. Estimated completion is 2015-03-17.
What interventions are being tested in trial NCT01771666?
The interventions under investigation include: Indocyanine Green (DRUG), Isosulfan blue (DRUG), SPY Elite Imaging (DEVICE), 99technetium-sulfur colloid radiolabel (DRUG).
Who is sponsoring clinical trial NCT01771666?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.